SEC Comment Letter 0000000000-25-002677 to Nanobiotix S.A. (NBTX)
Nanobiotix S.A.
Date: March 11, 2025 · CIK: 0001760854 · Accession: 0000000000-25-002677
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285604
Letter
Re: Nanobiotix S.A. Registration Statement on Form F-3 Filed March 6, 2025 File No. 333-285604 Dear Bart Van Rhijn:
March 11, 2025
Bart Van Rhijn Chief Financial Officer Nanobiotix S.A. 60, rue de Wattignies 75012 Paris, France
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Peter E. Devlin
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 11, 2025 Bart Van Rhijn Chief Financial Officer Nanobiotix S.A. 60, rue de Wattignies 75012 Paris, France Re: Nanobiotix S.A. Registration Statement on Form F-3 Filed March 6, 2025 File No. 333-285604 Dear Bart Van Rhijn: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter E. Devlin </TEXT> </DOCUMENT>